Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation
Open Access
- 1 February 2004
- Vol. 59 (2) , 100-104
- https://doi.org/10.1136/thorax.2003.006825
Abstract
Background: Leukotrienes play a key role in the pathophysiology of chronic asthma. Activation of leukotriene pathways is accompanied by rises in detectable urinary levels of leukotriene E4 (LTE4). The relationship between urinary LTE4 levels and factors associated with acute asthma has not been determined. Methods: Adults aged 15–54 years presenting with moderate to severe acute asthma were evaluated at emergency departments in 16 US sites. Forced expiratory volume in 1 second (FEV1) was measured during the first 60 minutes after arrival and at specified times until discharge or admission. Urine samples for measurement of LTE4 levels were obtained either on arrival at the study site and/or before discharge. Patients were seen 2 weeks later for follow up, at which time repeat FEV1 measurements and urine samples for LTE4 were obtained. Results: One hundred and eighty four patients were evaluated; LTE4 results from both the acute and follow up periods were available for analysis in 146. Urinary LTE4 levels were increased during asthma exacerbations compared with levels obtained 2 weeks later (geometric means 111.7 and 75.6 pg/mg creatinine, respectively, mean percentage change −32.3; 95% confidence interval (CI) for the mean percentage change −39.6 to −24.3, p1 and decline in LTE4 over the 2 week interval was significant (pr = 0.43). Conclusions: Activation of leukotriene pathways in acute asthma is correlated with the degree of airflow obstruction, and resolution of the asthma exacerbation is associated with a reduction in leukotriene levels.Keywords
This publication has 28 references indexed in Scilit:
- A Randomized Controlled Trial of Intravenous Montelukast in Acute AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Surveillance for asthma--United States, 1980-1999.2002
- The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivoJournal of Allergy and Clinical Immunology, 1995
- Recovery of Leukotriene E4from the Urine of Patients with Airway ObstructionAmerican Review of Respiratory Disease, 1992
- Leukotriene E4 elimination and metabolism in normal human subjects.Journal of Biological Chemistry, 1990
- Allergen-stimulated Release of Thromboxane A2and Leukotriene E4in Humans: Effect of IndomethacinAmerican Review of Respiratory Disease, 1990
- Deaths from asthma in Victoria: a 12‐month surveyThe Medical Journal of Australia, 1990
- The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individualsBiochemical and Biophysical Research Communications, 1987
- Leukotrienes and Airway ResponsesAmerican Review of Respiratory Disease, 1987
- REFERENCE SPIROMETRIC VALUES USING TECHNIQUES AND EQUIPMENT THAT MEET ATS RECOMMENDATIONSPublished by Elsevier ,1981